Acurion develops the OncoGaze™ platform, an AI-powered image analysis system that detects clinically actionable cancer biomarkers from routine pathology slides. The technology is positioned to extract biomarker insights without requiring additional tissue or specialized molecular testing. Acurion builds on foundational research from co-founder and CSO Ludmil Alexandrov, Ph.D., and has published in leading oncology and scientific journals while expanding clinical collaborations. The company says it is moving from validation toward deployment and is focusing on clinical and regulatory milestones. Acurion closed an oversubscribed $4.3 million seed round to fund clinical validation, platform development, regulatory preparation, and commercialization. The company expects to announce further clinical collaborations and regulatory progress in the coming months.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026